MediBeacon

This company develops a fluorescent tracer system that, when paired with an optical skin sensor, continuously monitors organ function in real-time. This technology allows for improved patient outcomes and optimized dosing strategies in intensive care units and operating rooms.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current methods for monitoring organ function often rely on invasive procedures or infrequent lab tests, limiting the ability to detect subtle changes in real-time, especially in critical care settings. Existing technologies may also lack the sensitivity to identify early indicators of organ dysfunction, potentially delaying necessary interventions and impacting patient outcomes.

Solution

MediBeacon has developed a system that utilizes fluorescent tracer agents and a transdermal optical sensor to continuously monitor organ function. The system detects changes in the levels of the fluorescent tracer agent over time via a sensor placed on the patient’s skin, displaying this information in real-time. This technology enables clinicians to gain insights into organ function without the need for invasive procedures, allowing for more timely and informed clinical decision-making. The initial application is the Transdermal GFR (tGFR) system, engineered to allow detection of the change in levels of a fluorescent GFR tracer agent over time via a sensor placed on the patient’s skin. The TGFR Monitor displays this information in the form of a transdermal GFR (tGFR) which may be useful in the understanding of kidney function.

Target Audience

The primary target audience includes clinicians in intensive care units and operating rooms, as well as researchers in preclinical nephrology.

Features

Transdermal sensor technology for non-invasive, continuous monitoring
Fluorescent tracer agents engineered to not interact with the body
Real-time data display of organ function metrics
Ability to measure GFR across the full range of human skin colors as quantified by the Fitzpatrick Skin Phototype (FSP)
Preclinical MX system for longitudinal GFR measurements in animals, compatible with conscious, freely-moving subjects
Preclinical MX system capable of measurements for up to 24 hours
Lab 3 software package for data transfer and analysis from the Preclinical MX system
Studio 3 advanced evaluation software for in-depth preclinical GFR analysis (sold separately)